![Mark Kowalski](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Kowalski
Plus aucun poste en cours
Fortune : 51 680 $ au 31/08/2026
Profil
Mark M.
Kowalski worked at AAIPharma, Inc. as Senior Director-Medical Affairs.
Served as Chief Medical Officer & VP-Regulatory Affairs at YM BioSciences, Inc., Viventia Biotech, Inc., and Viventia Bio, Inc. Held the position of Chief Research & Early Development Officer at Sierra Oncology, Inc. from 2017 to 2022.
Worked as Chief Medical Officer & Senior Vice President at Arbutus Biopharma Corp.
from 2013 to 2016.
Served as Chief Medical Officer at Eupraxia Pharmaceuticals, Inc. from 2023 to 2026.
Completed undergraduate studies at Rutgers State University of New Jersey.
Earned a doctorate from the University of Kansas Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/12/2025 | 8 000 ( 0,01% ) | 51 680 $ | 31/08/2026 |
Anciens postes connus de Mark Kowalski
| Sociétés | Poste | Fin |
|---|---|---|
| EUPRAXIA PHARMACEUTICALS INC. | Directeur Technique/Scientifique/R&D | 01/05/2026 |
| SIERRA ONCOLOGY, INC. | Directeur Technique/Scientifique/R&D | 10/03/2022 |
| ARBUTUS BIOPHARMA CORPORATION | Directeur Technique/Scientifique/R&D | 30/09/2016 |
Viventia Bio, Inc.
 Viventia Bio, Inc. BiotechnologyHealth Technology Focuses on designing, engineering and developing targeted protein therapeutics | Directeur Technique/Scientifique/R&D | - |
AAIPharma, Inc.
 AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides product development services to the pharmaceutical, biotechnology and medical device industries | Directeur Technique/Scientifique/R&D | - |
Formation de Mark Kowalski
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
53
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides product development services to the pharmaceutical, biotechnology and medical device industries | Commercial Services |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Produces cancer-related drug products | Health Technology |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and commercializes monoclonal antibody products | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Arbutus Biopharma Corp.
 Arbutus Biopharma Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics which targets viral diseases | Health Technology |
Eupraxia Pharmaceuticals, Inc.
 Eupraxia Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company focused on the development of delivered, extended-release alternatives to currently approved drugs | Health Technology |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Kansas Medical School
 University of Kansas Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Focuses on designing, engineering and developing targeted protein therapeutics | Health Technology |
